Spread Research - Nomad Foods Ltd. (NOMDN) New Issue Comment Nomad Foods

Report

Spread Research

Anthony Giret

EUR 246.20 For Business Accounts Only

New Issue Comment Nomad Foods

Nomad Foods, Iglo’s parent company, is refinancing its whole debt structure. Proceeds from the proposed issuance of €500m 7NC3 senior secured notes are earmarked to fund the....

19/04/2017 6 EN

Underlying

Nomad Foods Ltd.

See profile

VGG6564A1057 Mexican Stock Exchange British Virgin Islands

Provider

Spread Research

Spread Research is France's first Rating Agency, registered by ESMA (European Securities and Markets Authority) and a leading European Independent Credit Research firm, founded in 2004 and based in Lyon, France. Our experienced team offer key research services using a wide range of investment strategies and research methodologies for the High Yield, Emerging Markets, Convertibles and Loan Markets.

See profile

Analysts

Anthony Giret

Other Reports on these Companies

Vermilion Research

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 42.30

November 7, 2025 November 7, 2025 1 EN

Vermilion Research

Vital Signs: Actionable charts

EUR 42.30

February 25, 2025 February 25, 2025 1 EN

Vermilion Research

Vermilion Compass: Weekly Equity Strategy

Upgrading Staples and Health Care to Market Weight As the saying goes, "sector rotation is the lifeblood of a bull market." That appears to be exactly what is going on as we kick off 2024. Leadership areas that have significantly outperformed since the October 2023 lows are starting to pull back rather hard -- and on above average volume. This includes areas such as Technology (XLK), semiconductors (SMH), software (IGV), and the ARKK, IPO, and BITQ ETFs. This tells us a pause/pullback is likely for these high-octane areas, where technicals are short-term bearish, but still bullish longer-term...

EUR 42.30

January 3, 2024 January 3, 2024 1 EN

Gamenet 2q18 - sport payout change offsets regulation impact, goldbet to boost profitability

Gamenet, Italy’s No. 3 gaming firm, reported good 2Q18 results with stable sales yoy at €148m and EBITDA up 9% yoy to €21m, giving a 14.5% LTM margin as of June 2018 against 13.2% as of December 2017. Once again, Gamenet has adjusted its sport betting payout (winnings returned to players), lowering it to 80.3% during the quarter from 85.7% last year, to mitigate the impact from the tightening of regulation on gaming machines initiated in May 2017.

EUR 200.00

August 2, 2018 August 2, 2018 3 EN

Joan Sehim

Joan Sehim

INTRALOT- Special Comment

We initiated coverage in February with an Underweight recommendation on the Intralot 6.75% 2021 and 5.25% 2024 bonds, concluding that the group’s emerging profile and recent bad track record in tenders would weigh on bond prices. Since then, the 2021 and 2024 bonds have lost around 20-25 points to 86.375 and 78.375 respectively, now yielding at a high 10-12% to worst. The freefall started in May amid concerns over the group’s vulnerably to the Argentinean peso and Turkish lira (around 29% EBITDA), on top of contract losses in Morocco and South Carolina - in favor of Sisal and IGT respectively ...

EUR 200.00

August 1, 2018 August 1, 2018 3 EN

Benjamin Sabahi

Benjamin Sabahi

IQVIA- 2Q18 Comments

The world’s largest provider of healthcare information reported strong numbers for 2Q18. Reported revenues increased by 9% yoy in 2Q18 and +7.7% excluding FX. This was above market expectations and an intensification of the positive trends seen in 4Q17 (+5.5%) and 1Q18 (+5.2%) excluding FX impacts. This was down to a mix of accelerated organic growth coupled with M&A contributions, fully reflecting the investments in the next generation of clinical trials.

EUR 200.00

August 1, 2018 August 1, 2018 3 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

New Issue Comment Nomad Foods

Vital Signs: Actionable charts

Vital Signs: Actionable charts

Vermilion Compass: Weekly Equity Strategy

Gamenet 2q18 - sport payout change offsets regulation impact, goldbet to boost profitability

INTRALOT- Special Comment

IQVIA- 2Q18 Comments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe